




BACKGROUND

- Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide.
- Unmet medical need in immunotherapy is high for MSS patients and still present for MSI-H/dMMR patients. Tumor plasticity and treatment resistance are the main drivers of patient's relapse.
- Brenus Pharma develops a therapeutic cancer vaccine based on Stimulated Tumor Cells (STC): STC-1010 to educate the immune system to target patient's tumor cells harboring mechanism of relapse.
- This technology has already shown efficacy in immunocompetent mouse models and in ovo Chorio-allantoic model (CAM).







LB224- STC-1010 A NEW THERAPEUTIC VACCINE PROMOTES TUMOR CELL DEATH

A. BESSEDE¹, G. ALZEEB², C. TORTORELLI², JP. GUEGUAN¹, C. REY¹, L. CHALUS², B, PINTEUR², P, BRAVETTI², A, ITALIANO³

1. Explicyte, Bordeaux, France; 2. Brenus Pharma, Lyon, France; 3. Institut Bergonié, Bordeaux, France

STEP 0-1 4 DAYS -/- Media 1 or 2 +/- STC-1010 Monocytes Media 1: CD40L

Media 2: CD40L + LPS/INFg

Fig 2. Derived Mixed Lymphocyte Reaction CD8+ T cells priming and apoptosis of CRC cell lines

METHODS

Starting material : Human PBMC from 2 healthy donors

